N. Sacks

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
N Sacks, N. Sacks, Nathalie Sacks, Natalie Sacks
Publication record
37 papers · 1,700 citations · H-index 14

PAPERS

S48. Biomarker development for ipilimumab and prostate GVAX treatment
20140 citationsauthor #6
Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab
201494 citationsauthor #6
Abstract 1229: Pre-existing NY-ESO-1-specific T cell reactivity is associated with improved clinical outcome in castration resistant prostate cancer patients treated with Prostate GVAX and ipilimumab.
20130 citationsauthor #8
Abstract 496: Inflammatory responses with infiltrating DC and functional cytotoxic T lymphocytes in the dermal vaccination sites of GVAX/ipilimumab treated prostate cancer patients.
20130 citationsauthor #11
T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment
201390 citationsauthor #8
A Novel Colorectal Cancer Vaccine Consisting of Multiple Naturally Presented Peptides
20120 citationsauthor #28
Genitourinary tumors, prostate
20124 citationsauthor #167
Abstract 5381: Activation and frequency of myeloid subsets in peripheral blood is associated with clinical outcome in prostate cancer patients treated with Prostate GVAX and anti-CTLA4
20120 citationsauthor #7
Biomarkers for Clinical Outcome of Combined Immunotherapy with Granulocyte-Macrophage Colony-Stimulating Factor-Tranduced Allogeneic Prostate Cancer Cells (GVAX) and Ipilimumab in Castration-Resistant Prostate Cancer Patients (CRPC)
20121 citationsauthor #6
Lymphoid and myeloid biomarkers for clinical outcome of combined immunotherapy with granulocyte-macrophage colony-stimulating factor-tranduced allogeneic prostate cancer cells (GVAX) and ipilimumab in castration-resistant prostate cancer patients.
20121 citationsauthor #7
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
2012352 citationsauthor #17
Abstract 5512: Immune correlates of clinical response and survival in castration-resistant prostate cancer patients treated with prostate GVAX and anti-CTLA4 immunotherapy
20111 citationsauthor #12
Abstract 5588: T cell activation in relation to clinical responsiveness in patients with metastatic hormone-refractory prostate cancer receiving combined Prostate GVAX and anti-CTLA4 immunotherapy
20100 citationsauthor #8
Abstract B20: Immune vs. clinical response monitoring in patients with metastatic hormone-refractory prostate cancer receiving combined prostate GVAX and anti-CTLA4 immunotherapy
20101 citationsauthor #9
Abstract 2934: Increased type-2 T cell rates and coincidence of Th17 spikes with autoimmune events and PSA declines upon combined prostate GVAX and anti-CTLA4 immunotherapy
20100 citationsauthor #7
T Cell Activation, PSMA Seroconversion and Increased Th17 Rates are Associated with Favorable Clinical Outcome in Prostate Cancer Patients Treated with Prostate GVAX and Anti-CTLA4 Immunotherapy
20100 citationsauthor #10
Increased lymphopenia results in higher percentages of FoxP3+ T cells in patients reconstituted by PBMC adoptive transfer and vaccinated (41.36)
20090 citationsauthor #9
A PHASE 3 TRIAL OF GVAX IMMUNOTHERAPY FOR PROSTATE CANCER VS. DOCETAXEL PLUS PREDNISONE IN ASYMPTOMATIC, CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
200956 citationsauthor #9
Identification of antibody responses induced in patients with biochemically recurrent and castration-resistant prostate cancer receiving GVAX immunotherapy for prostate cancer
20080 citationsauthor #7
Abstract 2538: Dendritic and T cell functions in patients with metastatic hormone-refractory prostate cancer treated with GVAX immunotherapy for prostate cancer and ipilimumab
20080 citationsauthor #10
Phase 1/2 dose‐escalation study of a GM‐CSF‐secreting, allogeneic, cellular immunotherapy for metastatic hormone‐refractory prostate cancer
2008206 citationsauthor #8
Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC)
200848 citationsauthor #6
Granulocyte Macrophage Colony-Stimulating Factor–Secreting Allogeneic Cellular Immunotherapy for Hormone-Refractory Prostate Cancer
2007236 citationsauthor #2
A clinical development paradigm for cancer vaccines and related biologics.
2007274 citationsauthor #9
Biochemical and immunologic correlates of clinical response in a combination trial of the GM-CSF-gene transduced allogeneic prostate cancer immunotherapy and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHRPC)
200716 citationsauthor #6
Cyclophosphamide treatment and reconstitution with peripheral blood mononuclear cells does not reduce the frequency of circulating FoxP3 cells in vaccinated prostate cancer patients
20060 citationsauthor #7
Seminar article Granulocyte-macrophage colony-stimulating factortransduced allogeneic cancer cellular immunotherapy: The GVAX ® vaccine for prostate cancer
200611 citationsauthor #2
A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with a fully human anti-CTLA antibody (MDX-010, ipilimumab) in patients with metastatic hormone-refractory prostate cancer (mHRPC).
200641 citationsauthor #9
976: Immunotherapy with GVAX® Vaccine for Prostate Cancer Improves Predicted Survival in Metastatic Hormone Refractory Prostate Cancer: Results from Two Phase 2 Studies
200611 citationsauthor #7
Phase I/II study of GM-CSF gene-transduced allogeneic prostate cancer cellular immunotherapy (GVAX IT) in advanced prostate cancer patients made lymphopenic by chemotherapy and infused with autologous peripheral blood mononuclear cells (MC).
20062 citationsauthor #8
Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer.
2006167 citationsauthor #2
Metastatic Prostate Cancer Patients Treated With GVAX?? Vaccine for Prostate Cancer Develop Immunoreactivity to Filamin: Role of Filamin in Prostate Cancer Metastasis
20050 citationsauthor #6
Clinical and immunologic findings in a phase 2 study of a GM-CSF-secreting prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer (met HPRC)
200523 citationsauthor #9
A phase 2 study of an allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer (HRPC).
200446 citationsauthor #9
A Phase 2 Study of an Allogeneic GM-CSF Gene-Transduced Prostate Cancer Cell Line Vaccine in Patients with Metastatic Hormone-Refractory Prostate Cancer
20046 citationsauthor #4
Bone marrow transplantation for myelodysplastic syndrome – who? when? and which?
200215 citationsauthor #2
Approaches to successful knee replacement in hemophilia patients with inhibitors
20000 citationsauthor #3

TIMELINE

2000 0 citations

2002 15 citations

2004 52 citations

2005 23 citations

2006 232 citations

2007 526 citations

2008 254 citations

2009 56 citations

2010 1 citations

2011 1 citations

2012 358 citations

2013 90 citations

2014 94 citations

COAUTHOR MAP

CONCEPT FOOTPRINT